Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Neoplasms|Malignant Neoplasm of Breast
Interventions: DRUG: Trastuzumab|DRUG: Ibrutinib 560 mg|DRUG: Ibrutinib 840 mg|DRUG: Ibrutinib 420 mg
Sponsor: US Oncology Research
Collaborators: AbbVie|Pharmacyclics LLC.